Want to see JP:4595 full AI Analyst Report?
Top Page
Mizuho Medy Co., Ltd.
(4595)
Select Model
Select Model
Rating:75Outperform
Price Target:
¥1,857.00
▲(5.93% Upside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by strong financial quality (high profitability and a debt-free balance sheet) and supportive valuation (low P/E and high dividend yield). These positives are tempered by weaker near-term cash flow momentum and mixed technical signals with subdued momentum.
Positive Factors
High Profitability
Sustained ~30% net margins indicate durable pricing power or cost advantage in its specialty/generic niche. High margins support ongoing reinvestment, R&D and dividend capacity, giving the company long-term earnings resilience versus lower‑margin peers.
Negative Factors
Deteriorating Cash Conversion (2025)
A recent drop where operating cash flow lags net income signals weaker earnings quality and potential working capital or collection stress. If persistent, this reduces free cash available for investment and dividends and raises cyclicality of reported profits.
Read all positive and negative factors
Positive Factors
Negative Factors
High Profitability
Sustained ~30% net margins indicate durable pricing power or cost advantage in its specialty/generic niche. High margins support ongoing reinvestment, R&D and dividend capacity, giving the company long-term earnings resilience versus lower‑margin peers.
Read all positive factors
Mizuho Medy Co., Ltd. (4595) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥33.03B
Dividend Yield5.77%
Average Volume (3M)64.11K
Price to Earnings (P/E)10.2
Beta (1Y)0.37
Revenue Growth0.75%
EPS Growth-2.33%
CountryJP
Employees193
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)169.41
Shares Outstanding19,051,200
10 Day Avg. Volume72,640
30 Day Avg. Volume64,113
Financial Highlights & Ratios
PEG Ratio-1.03
Price to Book (P/B)1.74
Price to Sales (P/S)2.88
P/FCF Ratio19.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)152.2
Revenue Forecast (FY)¥10.90B
Mizuho Medy Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 1977 and headquartered in Tosu, Japan, Mizuho Medy Co.,Ltd. specializes in the research, development, production, and distribution of in-vitro diagnostic solutions, complemented by scientific and technical information services. Whil...
How the Company Makes Money
null...
Mizuho Medy Co., Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.82B | 11.26B | 11.43B | 10.99B | 17.58B | 12.89B |
| Gross Profit | 7.40B | 7.78B | 8.04B | 8.03B | 14.05B | 9.61B |
| EBITDA | 4.44B | 4.91B | 5.10B | 5.40B | 11.26B | 6.87B |
| Net Income | 3.23B | 3.42B | 3.77B | 3.77B | 7.84B | 4.82B |
Balance Sheet | ||||||
| Total Assets | 20.99B | 22.38B | 20.73B | 18.95B | 19.10B | 12.19B |
| Cash, Cash Equivalents and Short-Term Investments | 13.06B | 10.82B | 11.25B | 10.13B | 8.70B | 4.33B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.43B | 3.69B | 3.37B | 3.27B | 4.82B | 4.16B |
| Stockholders Equity | 18.55B | 18.68B | 17.35B | 15.68B | 14.28B | 8.03B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.70B | 3.05B | 3.73B | 5.99B | 5.44B |
| Operating Cash Flow | 0.00 | 1.96B | 3.35B | 3.99B | 6.17B | 5.60B |
| Investing Cash Flow | 0.00 | -7.28B | -307.00M | -270.45M | -1.55B | -159.74M |
| Financing Cash Flow | 0.00 | -2.08B | -2.09B | -2.38B | -1.57B | -1.16B |
Mizuho Medy Co., Ltd. Technical Analysis
Positive
1753.00
Price Trends
1670.59
Positive
1688.77
Positive
1682.74
Positive
Market Momentum
16.46
Negative
63.45
Neutral
87.44
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4595, the sentiment is Positive. The current price of 1753 is above the 20-day moving average (MA) of 1696.05, above the 50-day MA of 1670.59, and above the 200-day MA of 1682.74, indicating a bullish trend. The MACD of 16.46 indicates Negative momentum. The RSI at 63.45 is Neutral, neither overbought nor oversold. The STOCH value of 87.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4595.
Mizuho Medy Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥33.03B | 10.23 | ― | 6.29% | 0.75% | -2.33% | |
68 Neutral | ¥112.63B | 12.86 | 5.81% | 2.34% | 14.72% | 52.55% | |
66 Neutral | ¥56.84B | 12.93 | ― | 2.52% | ― | -7.20% | |
60 Neutral | ¥48.11B | 15.50 | 5.06% | 2.56% | 20.36% | -5.53% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ¥5.70B | -45.84 | ― | 3.21% | 0.60% | -131.22% | |
44 Neutral | ¥5.66B | -7.00 | ― | ― | 364.72% | 18.43% |
* General Sector Average
JP:4595
Mizuho Medy Co., Ltd.
1,730.00
233.80
15.63%
JP:4554
Fuji Pharma Co., Ltd.
1,862.00
402.65
27.59%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,290.00
236.34
7.74%
JP:4539
Nippon Chemiphar Co., Ltd.
1,574.00
3.84
0.24%
JP:4886
ASKA Pharmaceutical Holdings Co., Ltd.
2,138.00
-244.70
-10.27%
JP:4892
Cyfuse Biomedical K.K.
570.00
-52.00
-8.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.